DOXYCYCLINE HYCLATE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for doxycycline hyclate and what is the scope of freedom to operate?
Doxycycline hyclate
is the generic ingredient in fifteen branded drugs marketed by Pliva, Mayne Pharma, Warner Chilcott, Bausch, Chartwell Rx, Teva, Actavis Labs Fl Inc, Ajanta Pharma Ltd, Alembic, Amneal Pharms, Changzhou Pharm, Chartwell, Halsey, Heather, Hikma Intl Pharms, Interpharm, Mutual Pharm, Nesher Pharms, Nostrum Labs Inc, Par Pharm, Pvt Form, Ranbaxy, Strides Pharma, Sun Pharm Industries, Superpharm, Watson Labs, Zhejiang Yongtai, Zydus Lifesciences, Collagenex, Pfizer, Fresenius Kabi Usa, Rachelle, Hikma, Mylan Labs Ltd, Zydus Pharms, Endo Operations, Gland Pharma Ltd, Heritage, Lupin Ltd, Slate Run Pharma, West-ward Pharms Int, Den-mat, Actavis Elizabeth, Aurobindo Pharma Usa, Impax Labs Inc, Lupin, Prinston Inc, Rising, Acella, Amneal, Amneal Pharms Co, Apotex, Avet Lifesciences, Caribe Holdings, Chartwell Molecular, Dr Reddys Labs Sa, Epic Pharma Llc, Heritage Pharma, Larken Labs, Mylan, Novel Labs Inc, Oryza, Praxgen, Torrent, Chartwell Pharma, and Galderma Labs Lp, and is included in one hundred and one NDAs. There are four patents protecting this compound and seven Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.Doxycycline hyclate has two patent family members in two countries.
There are fifteen drug master file entries for doxycycline hyclate. Seventy-four suppliers are listed for this compound.
Summary for DOXYCYCLINE HYCLATE
International Patents: | 2 |
US Patents: | 4 |
Tradenames: | 15 |
Applicants: | 66 |
NDAs: | 101 |
Drug Master File Entries: | 15 |
Finished Product Suppliers / Packagers: | 74 |
Raw Ingredient (Bulk) Api Vendors: | 194 |
Clinical Trials: | 25 |
Drug Prices: | Drug price trends for DOXYCYCLINE HYCLATE |
Drug Sales Revenues: | Drug sales revenues for DOXYCYCLINE HYCLATE |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for DOXYCYCLINE HYCLATE |
What excipients (inactive ingredients) are in DOXYCYCLINE HYCLATE? | DOXYCYCLINE HYCLATE excipients list |
DailyMed Link: | DOXYCYCLINE HYCLATE at DailyMed |
Recent Clinical Trials for DOXYCYCLINE HYCLATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Chinese University of Hong Kong | Phase 4 |
The Jinnah Postgraduate Medical Centre, Karachi, Sindh 75510, Pakistan | Phase 1/Phase 2 |
Zhuzhou Qianjin Pharmaceutical Co., Ltd., 801, Zhuzhou, China | Phase 1/Phase 2 |
Pharmacology for DOXYCYCLINE HYCLATE
Drug Class | Tetracycline-class Drug |
Anatomical Therapeutic Chemical (ATC) Classes for DOXYCYCLINE HYCLATE
Paragraph IV (Patent) Challenges for DOXYCYCLINE HYCLATE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
DORYX MPC | Delayed-release Tablets | doxycycline hyclate | 60 mg and 120 mg | 050795 | 1 | 2017-09-28 |
DORYX MPC | Delayed-release Tablets | doxycycline hyclate | 50 mg | 050795 | 1 | 2015-11-05 |
DORYX MPC | Delayed-release Tablets | doxycycline hyclate | 80 mg | 050795 | 1 | 2015-07-01 |
DORYX MPC | Delayed-release Tablets | doxycycline hyclate | 200 mg | 050795 | 1 | 2014-05-19 |
DORYX MPC | Delayed-release Tablets | doxycycline hyclate | 150 mg | 050795 | 1 | 2008-12-19 |
US Patents and Regulatory Information for DOXYCYCLINE HYCLATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Zydus Pharms | DOXYCYCLINE HYCLATE | doxycycline hyclate | TABLET, DELAYED RELEASE;ORAL | 206772-003 | Dec 21, 2018 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Dr Reddys Labs Sa | DOXYCYCLINE HYCLATE | doxycycline hyclate | TABLET;ORAL | 208765-002 | Jun 14, 2017 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Watson Labs | DOXYCYCLINE HYCLATE | doxycycline hyclate | TABLET;ORAL | 062392-001 | Mar 31, 1983 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Actavis Labs Fl Inc | DOXYCYCLINE HYCLATE | doxycycline hyclate | CAPSULE;ORAL | 062031-002 | Oct 13, 1982 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DOXYCYCLINE HYCLATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Mayne Pharma | DORYX | doxycycline hyclate | TABLET, DELAYED RELEASE;ORAL | 050795-006 | Dec 19, 2014 | ⤷ Sign Up | ⤷ Sign Up |
Mayne Pharma | DORYX | doxycycline hyclate | TABLET, DELAYED RELEASE;ORAL | 050795-002 | May 6, 2005 | ⤷ Sign Up | ⤷ Sign Up |
Mayne Pharma | DORYX | doxycycline hyclate | TABLET, DELAYED RELEASE;ORAL | 050795-003 | Jun 20, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Mayne Pharma | DORYX MPC | doxycycline hyclate | TABLET, DELAYED RELEASE;ORAL | 050795-007 | May 20, 2016 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for DOXYCYCLINE HYCLATE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
World Intellectual Property Organization (WIPO) | 2006045152 | ⤷ Sign Up | |
Australia | 2005299253 | Improved tabletting process | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.